Role of Probiotics in Managing of Helicobacter Pylori Infection: A Review.
Background:Helicobacter pyloriis a prevalent pathogen which is considered as an etiological cause for gastroduodenal ulcers, and a substantial risk factor for gastric malignancies. The vital factor to take into account is that roughly half of the world's population is infected with this bacterium. However, most subjects colonized remain asymptomatic and do not require any treatment. Several antimicrobial agents such as amoxicillin, clarithromycin and metronidazole are used to eradicate the infection. However, these drug regiments do not eradicateH. pyloriin all patients because of the anti-drug resistance.Aim:In this review we aim to discuss the role and mechanisms of probiotics, as supportive medicines, in management ofH. pyloriinfection.Methods:We have reviewed the published articles in PubMed and Medline databases. Also, abstracts presented in international conferences on the management ofH. pyloriinfections and treatment protocol, have been thoroughly reviewed.Results:The overall trend in the literature indicates the usefulness of probiotics in controllingH. pyloriinfection. This bacterium is among the most studied human pathogens regarding the efficacy of probiotics for treating its infection. Nevertheless, some studies suggest that probiotics do not efficiently eradicateH. pyloribut retain the number of this bacterium at low levels inside the human stomach.Conclusion:The analyzed literature suggest that when probiotics are consumed in conjunction with antibiotics, the eradication rate may be improved through modulating the immune response and decreasing the adverse effects of routine drugs leading to gastroprotection.
Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Taiebeh
T
Kafshdooz
Liver and Gastrointestinal disease research center, Tabriz University of Medical Sciences, Tabriz, Iran.
Abolfazl
A
Akbarzadeh
Department of anatomical sciences, Medicine faculty, Tabriz University of Medical Science, Iran.
Abbas
A
Majdi Seghinsara
Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Moghadam
M
Pourhassan
Department of anatomical sciences, Medicine faculty, Tabriz University of Medical Science, Iran.
Hamid Tayefi
HT
Nasrabadi
Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Morteza
M
Milani
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination / Q000379:methods / Q000639:trends; D016481:Helicobacter Infections / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy*; D016480:Helicobacter pylori; D006801:Humans; D010437:Peptic Ulcer / Q000382:microbiology*; D019936:Probiotics / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents